Xiaohong Liu

Dr. Xiaohong Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
XLXin Liu
Xin Liu
YHYi Hu
Yi Hu
CLCairong Li
Cairong Li
JCJiayu Chen
Jiayu Chen
XLXiaohong Liu
Xiaohong Liu
XXXiming Xu
Ximing Xu
Hepatocellular carcinoma (HCC) is one of the most common cancers and the fourth leading cause of death in men. YEATS domain containing 2 (YEATS2) gene encodes a scaffolding subunit of the ATAC complex. We found that YEATS2 was upregulated in HCC tissues and was associated with a poor prognosis. However, the role of YEATS2 in HCC remains unclear. The purpose of this study was to investigate the effect of YEATS2 on the progression of HCC and to elucidate its related mechanisms. We found that overexpression of YEATS2 promoted tumor cell proliferation, migration, and invasion through the PI3K/AKT signaling pathway and regulation of extracellular matrix. These findings help to understand the role of YEATS2 in HCC, and YEATS2 may become a new target for HCC therapy.

5 September 2022 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
XLXiaohong Liu
Xiaohong Liu
DCDedong Cao
Dedong Cao
HLHui Liu
Hui Liu
DKDong Ke
Dong Ke
XKXiaokang Ke
Xiaokang Ke
XXXiming Xu
Ximing Xu
Purpose: This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction. Patients and methods: Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram. Results: Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data. Conclusion: Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.

23 June 2023 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XLXiaohong Liu
Xiaohong Liu
DCDedong Cao
Dedong Cao
HLHui Liu
Hui Liu
XKXiaoKang Ke
XiaoKang Ke
XLXin Liu
Xin Liu
XXXiming Xu
Ximing Xu

26 August 2026 in Medcomm
Verified
Journal Article
Open access
PDF file
YSYujin Shi
Yujin Shi
BHBin Huang
Bin Huang
XLXiaohong Liu
Xiaohong Liu
YLYalan Liu
Yalan Liu
QHQinyong Hu
Qinyong Hu
HRHong‐Gang Ren
Hong‐Gang Ren
Associations between various genetic variants and the risk of hepatocellular carcinoma (HCC) have been extensively explored but produced contradictory results. The aim of the present systematic meta‐analysis was to determine and validate genetic variants that are associated with HCC risk. Two‐step literature searches of PubMed, Embase, Web of Science, and Google Scholar databases and various meta‐analyses were performed, and a comprehensive field synopsis and epidemiological evidence were provided. A total of 20,081 publications were identified, of which 830 were deemed eligible for inclusion. Eventually, 36 variants in 27 genes were identified to be associated with HCC risk. Moreover, cumulative epidemiological evidence of an association was graded as moderate for nine variants in eight genes ( ESR1 rs2234693, GRP78 rs430397, HLA‐DP rs3077, HLA‐DQ rs2856718, MnSOD rs4880, TNFα rs361525, HFE rs1800562 and rs1799945, and UGT1A7 High/Low) and strong for three variants in three genes ( IL‐1B rs1143627, COL18A1 rs7499, and NQO1 rs1800566); HFE rs1800562 was deemed to have a false‐positive association. Thus, 11 variants in 11 genes were identified to be associated with HCC risk. This synopsis helps elucidate the mechanisms of carcinogenesis of HCC and provides insights into the early diagnosis and novel treatments of HCC by targeting those potential genes.